Here are the 10-Q quarterly reports from Humacyte, Inc. Warrant (HUMAW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HUMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMAW filings page.
Humacyte, Inc. reported modest commercialization progress and continued heavy losses for the six months ended June 30, 2026. Total revenue was $0.9 million, up slightly from $0.8 million a year earlier, driven by Symvess product revenue of $0.9 million.
Operating expenses remained high, with research and development of $37.6 million and general and administrative of $16.0 million, leading to an operating loss of $55.9 million and a net loss of $54.4 million for the six-month period. Net cash used in operating activities was $47.2 million. The company had cash and cash equivalents of $79.9 million and an accumulated deficit of $781.3 million as of June 30, 2026.
Humacyte raised capital through a $18.3 million March 2026 registered direct equity offering, a $53.8 million June 2026 underwritten public offering, and $4.6 million of ATM sales, and has a $40 million term loan outstanding plus remaining capacity under a $50 million equity line. Management states that current resources are insufficient to fund operations for 12 months without additional cash generation or financing, and discloses substantial doubt about its ability to continue as a going concern.
Humacyte, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, compared with net income of $39.1 million a year earlier, as favorable fair value movements on earnout and warrant liabilities were much smaller than in 2025.
Total revenue was $0.5 million, with product revenue from Symvess increasing to $493,000 while contract revenue declined. Operating expenses rose to $29.4 million, driven mainly by higher research and development spending of $19.5 million.
Humacyte used $25.1 million of cash in operating activities and ended the quarter with cash and cash equivalents of $48.5 million. Management states that these resources are not sufficient to fund operations beyond one year without stronger Symvess sales and/or additional financing, raising substantial doubt about the company’s ability to continue as a going concern.